Total non-dilutive funding of up to USD 159 million upon completion of predefined milestones, including near-term committed funding of USD 6 ...
The contract replaces BARDA’s agreement with Venatorx, the company that licensed the oral antibiotic to Basilea.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback